{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(1)"],"submitter":["Cheng Y"],"pubmed_abstract":["<h4>Importance</h4>Patients with extensive-stage small cell lung cancer (ES-SCLC) have poor prognoses and unmet medical needs.<h4>Objective</h4>To evaluate the efficacy and safety of toripalimab plus etoposide and platinum-based chemotherapy (EP) vs placebo plus EP as a first-line treatment for patients with ES-SCLC.<h4>Design, setting, and participants</h4>This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (EXTENTORCH study) enrolled patients from September 26, 2019, to May 20, 2021, and was conducted at 49 sites in China. Eligible patients had histologically or cytologically confirmed ES-SCLC without previous systemic antitumor therapy for ES-SCLC. Data were analyzed between May 6, 2023, and June 1, 2024.<h4>Interventions</h4>Patients were randomized (1:"],"journal":["JAMA oncology"],"pagination":["16-25"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11565370"],"repository":["biostudies-literature"],"pubmed_title":["Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial."],"pmcid":["PMC11565370"],"pubmed_authors":["Zhang G","Hu S","Huang C","Wu L","Fang J","Huang J","Wang B","Wang D","Zhang M","Zhang S","Wang J","Wu H","Jin F","Wang R","Chen Y","Xia B","Gu K","Wang Y","Chen S","Yang H","Xu K","Li C","Chen G","Sun Y","Li M","Li Y","Hu J","Yang R","Jiang L","Liu L","Ding C","Fu X","Bi M","Han Z","Yu J","Cheng Y","Zhao Y","Yi T","Liu Y","Zhou C","Zheng WE","Yu W","Zhou M","Pan Y","Gu S","Bao Y","Lv D","Fan Q","Zhang W","Zhang Z","Huang X","Zhang X","Luo X"],"additional_accession":[]},"is_claimable":false,"name":"Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.","description":"<h4>Importance</h4>Patients with extensive-stage small cell lung cancer (ES-SCLC) have poor prognoses and unmet medical needs.<h4>Objective</h4>To evaluate the efficacy and safety of toripalimab plus etoposide and platinum-based chemotherapy (EP) vs placebo plus EP as a first-line treatment for patients with ES-SCLC.<h4>Design, setting, and participants</h4>This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (EXTENTORCH study) enrolled patients from September 26, 2019, to May 20, 2021, and was conducted at 49 sites in China. Eligible patients had histologically or cytologically confirmed ES-SCLC without previous systemic antitumor therapy for ES-SCLC. Data were analyzed between May 6, 2023, and June 1, 2024.<h4>Interventions</h4>Patients were randomized (1:","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-05T13:21:43.811Z","creation":"2026-05-17T03:13:12.656Z"},"accession":"S-EPMC11565370","cross_references":{"pubmed":["39541202"],"doi":["10.1001/jamaoncol.2024.5019"]}}